세계의 중증 허혈성 하지(CLI) 치료 시장 규모 조사 : 치료별, 약물별, 기기별 및 지역별 예측(2022-2032년)

The Global Critical Limb Ischemia (CLI) Treatment Market was valued at USD 4.02 billion in 2023 and is anticipated to grow at a robust CAGR of 7.32% over the forecast period 2024-2032. Critical Limb Ischemia is a severe condition characterized by significant obstruction of the arteries, which drastically reduces blood flow to the extremities. The treatment aims to restore circulation and prevent limb amputation. Initial treatments include lifestyle changes, medication to improve blood flow, and wound care. Revascularization, either through angioplasty or bypass surgery, is a primary treatment method. In severe cases, amputation might be necessary. Additionally, pain management and physical therapy play crucial roles in improving patient quality of life. Early intervention is essential for optimal outcomes.

The market is experiencing significant growth, driven by key factors such as an aging population and the rising prevalence of diseases associated with vascular complications, including diabetes and cardiovascular disorders. As the global demographic landscape shifts towards older age groups, the incidence of critical limb ischemia increases, necessitating effective treatments. The market response to this demand is evident in the proliferation of innovative therapeutic interventions and technological advancements. Companies are strategically positioning themselves to capitalize on this growing demand by focusing on research, development, and commercialization of advanced treatment solutions. Technological advancements in endovascular therapies are significantly transforming the treatment landscape for critical limb ischemia. Innovations in minimally invasive procedures, such as endovascular revascularization, have revolutionized the market by enabling more precise and less invasive treatment options. The integration of advanced imaging modalities and catheter-based interventions has improved the accuracy of diagnosis and targeted treatment of CLI, leading to shorter recovery times and better patient outcomes.

Increasing awareness and early diagnosis initiatives are also playing a pivotal role in market growth. Heightened awareness campaigns have educated both healthcare professionals and the general population about the risks and symptoms of CLI, leading to more proactive medical interventions. Early diagnosis ensures timely treatment, improving patient outcomes and reducing the economic burden associated with advanced treatments. However, the high cost of treatment remains a significant challenge for the market. The complexity and advanced nature of CLI treatments contribute to the high overall costs, which can limit accessibility for some patients.

Regionally, North America dominates the market, driven by high prevalence of cardiovascular risk factors, advanced healthcare infrastructure, and robust research and development ecosystems. The Asia Pacific region is expected to witness the fastest growth due to the rising incidence of respiratory maladies, improved healthcare infrastructure, and increasing healthcare awareness.

Major market players included in this report are:

• Medtronic plc
• LimFlow SA
• Cynata Therapeutics Ltd
• Cardiovascular Systems, Inc.
• Eli Lilly and Company
• Abbott Laboratories, Inc.
• Rexgenero Ltd.
• Cesca Therapeutics (ThermoGenesis Holdings, Inc)
• Teva Pharmaceuticals Industries Limited
• Micro Medical Solutions

The detailed segments and sub-segment of the market are explained below:

By Treatment:

• Drugs
• Devices

By Drugs:

• Antiplatelet Drugs
• Antihypertensive Agents
• Lipid-lowering Agents
• Antithrombotic Agents
• Others

By Devices:

• Embolic Protection Devices
• Peripheral Dilatation System
• Balloon Dilators
• Vascular Stents

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Critical Limb Ischemia (CLI) Treatment Market Executive Summary

• 1.1. Global Critical Limb Ischemia (CLI) Treatment Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Treatment
  • 1.3.2. By Drugs
  • 1.3.3. By Devices
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Critical Limb Ischemia (CLI) Treatment Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Critical Limb Ischemia (CLI) Treatment Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Aging Population and Increasing Disease Prevalence
  • 3.1.2. Technological Advancements in Endovascular Therapies
  • 3.1.3. Increasing Awareness and Early Diagnosis
• 3.2. Market Challenges
  • 3.2.1. High Treatment Costs
• 3.3. Market Opportunities
  • 3.3.1. Emerging Markets
  • 3.3.2. Innovation in Treatment Modalities

Chapter 4. Global Critical Limb Ischemia (CLI) Treatment Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Critical Limb Ischemia (CLI) Treatment Market Size & Forecasts by Treatment 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Critical Limb Ischemia (CLI) Treatment Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Drugs
  • 5.2.2. Devices

Chapter 6. Global Critical Limb Ischemia (CLI) Treatment Market Size & Forecasts by Drugs 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Critical Limb Ischemia (CLI) Treatment Market: Drugs Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Antiplatelet Drugs
  • 6.2.2. Antihypertensive Agents
  • 6.2.3. Lipid-lowering Agents
  • 6.2.4. Antithrombotic Agents
  • 6.2.5. Others

Chapter 7. Global Critical Limb Ischemia (CLI) Treatment Market Size & Forecasts by Devices 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Critical Limb Ischemia (CLI) Treatment Market: Devices Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Embolic Protection Devices
  • 7.2.2. Peripheral Dilatation System
  • 7.2.3. Balloon Dilators
  • 7.2.4. Vascular Stents

Chapter 8. Global Critical Limb Ischemia (CLI) Treatment Market Size & Forecasts by Region 2022-2032

• 8.1. North America Critical Limb Ischemia (CLI) Treatment Market
  • 8.1.1. U.S. Critical Limb Ischemia (CLI) Treatment Market
    • 8.1.1.1. Treatment breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Drugs breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Devices breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Critical Limb Ischemia (CLI) Treatment Market
• 8.2. Europe Critical Limb Ischemia (CLI) Treatment Market
  • 8.2.1. U.K. Critical Limb Ischemia (CLI) Treatment Market
  • 8.2.2. Germany Critical Limb Ischemia (CLI) Treatment Market
  • 8.2.3. France Critical Limb Ischemia (CLI) Treatment Market
  • 8.2.4. Spain Critical Limb Ischemia (CLI) Treatment Market
  • 8.2.5. Italy Critical Limb Ischemia (CLI) Treatment Market
  • 8.2.6. Rest of Europe Critical Limb Ischemia (CLI) Treatment Market
• 8.3. Asia-Pacific Critical Limb Ischemia (CLI) Treatment Market
  • 8.3.1. China Critical Limb Ischemia (CLI) Treatment Market
  • 8.3.2. India Critical Limb Ischemia (CLI) Treatment Market
  • 8.3.3. Japan Critical Limb Ischemia (CLI) Treatment Market
  • 8.3.4. Australia Critical Limb Ischemia (CLI) Treatment Market
  • 8.3.5. South Korea Critical Limb Ischemia (CLI) Treatment Market
  • 8.3.6. Rest of Asia Pacific Critical Limb Ischemia (CLI) Treatment Market
• 8.4. Latin America Critical Limb Ischemia (CLI) Treatment Market
  • 8.4.1. Brazil Critical Limb Ischemia (CLI) Treatment Market
  • 8.4.2. Mexico Critical Limb Ischemia (CLI) Treatment Market
  • 8.4.3. Rest of Latin America Critical Limb Ischemia (CLI) Treatment Market
• 8.5. Middle East & Africa Critical Limb Ischemia (CLI) Treatment Market
  • 8.5.1. Saudi Arabia Critical Limb Ischemia (CLI) Treatment Market
  • 8.5.2. South Africa Critical Limb Ischemia (CLI) Treatment Market
  • 8.5.3. Rest of Middle East & Africa Critical Limb Ischemia (CLI) Treatment Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Medtronic plc
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. LimFlow SA
  • 9.3.3. Cynata Therapeutics Ltd
  • 9.3.4. Cardiovascular Systems, Inc.
  • 9.3.5. Eli Lilly and Company
  • 9.3.6. Abbott Laboratories, Inc.
  • 9.3.7. Rexgenero Ltd.
  • 9.3.8. Cesca Therapeutics (ThermoGenesis Holdings, Inc)
  • 9.3.9. Teva Pharmaceuticals Industries Limited
  • 9.3.10. Micro Medical Solutions

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes